Rothschild & CO Asset Management Us Inc. Neurocrine Biosciences Inc Transaction History

Rothschild & CO Asset Management Us Inc.

$6.56 Billion
Q4 2022

A detailed history of Rothschild & CO Asset Management Us Inc. transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Rothschild & CO Asset Management Us Inc. holds 57,111 shares of NBIX stock, worth $7.17 Million. This represents 0.1% of its overall portfolio holdings.

Number of Shares

57,111

Previous 64,419 11.34%

Holding current value

$7.17 Million

Previous $6.84 Million 0.31%

% of portfolio

0.1%

Previous 0.12%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$106.72 - $127.06 $779,909 - $928,554	-7,308 Reduced 11.34%	57,111 $6.82 Million
Q3 2022 Nov 07, 2022	SELL	$92.03 - $107.81 $878,794 - $1.03 Million	-9,549 Reduced 12.91%	64,419 $6.84 Million
Q2 2022 Aug 09, 2022	SELL	$75.79 - $100.07 $344,541 - $454,918	-4,546 Reduced 5.79%	73,968 $7.21 Million
Q1 2022 May 13, 2022	SELL	$72.45 - $94.81 $1.65 Million - $2.16 Million	-22,753 Reduced 22.47%	78,514 $7.36 Million
Q4 2021 Feb 11, 2022	BUY	$79.65 - $106.22 $995,226 - $1.33 Million	12,495 Added 14.08%	101,267 $8.63 Million
Q3 2021 Nov 09, 2021	SELL	$86.18 - $99.03 $597,399 - $686,475	-6,932 Reduced 7.24%	88,772 $8.51 Million
Q2 2021 Aug 16, 2021	SELL	$89.43 - $102.27 $968,884 - $1.11 Million	-10,834 Reduced 10.17%	95,704 $9.31 Million
Q1 2021 May 14, 2021	SELL	$87.57 - $119.4 $4.22 Million - $5.75 Million	-48,152 Reduced 31.13%	106,538 $10.4 Million
Q4 2020 Feb 08, 2021	BUY	$86.91 - $108.33 $1.71 Million - $2.13 Million	19,647 Added 14.55%	154,690 $14.8 Million
Q3 2020 Nov 09, 2020	SELL	$96.16 - $135.15 $2.81 Million - $3.95 Million	-29,208 Reduced 17.78%	135,043 $13 Million
Q2 2020 Aug 10, 2020	SELL	$85.09 - $130.36 $3.84 Million - $5.89 Million	-45,170 Reduced 21.57%	164,251 $20 Million
Q1 2020 May 14, 2020	SELL	$75.11 - $113.76 $1.38 Million - $2.09 Million	-18,399 Reduced 8.08%	209,421 $18.1 Million
Q4 2019 Feb 12, 2020	SELL	$86.8 - $118.57 $915,219 - $1.25 Million	-10,544 Reduced 4.42%	227,820 $24.5 Million
Q3 2019 Nov 08, 2019	BUY	$83.82 - $101.5 $2.37 Million - $2.87 Million	28,276 Added 13.46%	238,364 $21.5 Million
Q2 2019 Jul 25, 2019	BUY	$72.24 - $91.27 $4.34 Million - $5.48 Million	60,013 Added 39.99%	210,088 $17.7 Million
Q1 2019 May 08, 2019	BUY	$69.31 - $91.53 $4.05 Million - $5.35 Million	58,429 Added 63.76%	150,075 $13.2 Million
Q4 2018 Feb 05, 2019	BUY	$68.32 - $124.36 $1.7 Million - $3.09 Million	24,879 Added 37.26%	91,646 $6.54 Million
Q3 2018 Nov 13, 2018	BUY	$98.88 - $125.85 $6.6 Million - $8.4 Million	66,767 New	66,767 $8.21 Million
Q1 2018 May 08, 2018	SELL	$75.88 - $92.43 $2.01 Million - $2.45 Million	-26,525 Closed	0 $0
Q4 2017 Feb 12, 2018	SELL	$58.53 - $77.59 $656,706 - $870,559	-11,220 Reduced 29.73%	26,525 $2.06 Million
Q3 2017 Nov 08, 2017	BUY	$47.97 - $61.28 $1.81 Million - $2.31 Million	37,745	37,745 $2.31 Million

Others Institutions Holding NBIX

# of Institutions

629

Shares Held

94.2M

Call Options Held

692K

Put Options Held

406K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $12B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rothschild & CO Asset Management Us Inc., based on Form 13F filings with the SEC.

News

Stay updated on Rothschild & CO Asset Management Us Inc. with notifications on news.

Account

Rothschild & CO Asset Management Us Inc. Neurocrine Biosciences Inc Transaction History